Avandia Committee Review: FDA Puts Five Options On Table For Advisory Panels
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisors could recommend that GlaxoSmithKline's diabetes drug be taken off the market, that the warnings on its label be downgraded, or a range of in-between options.